{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T22:10:03Z","timestamp":1742508603271,"version":"3.40.1"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic with the continuous evolution of the virus into variants such as Alpha, Beta, Delta, Omicron and others necessitates an on-going surveillance and evaluation of vaccine effectiveness (VE).This study focuses on assessing the real-world performance of the Pfizer-BioNTech (BNT162b2) vaccine against the Omicron variant. This study employs a test-negative, case-control design, a methodology commonly utilized for estimating the VE in influenza studies. It evaluates SARS-CoV-2 test results in individuals aged 50 and older who had influenza-like illness (ILI) or COVID-like illness (CLI) symptoms and presented to the sentinel sites, classifying positive cases as \u201ccases\u201d and negative as \u201ccontrols.\u201d Data collection was done through a standardized questionnaire administered by the Epidemiological Surveillance Unit (ESU) COVID-19 team via phone interviews. Logistic regression analysis was performed to measure the association, taking into account all confounding factors. The results indicate a 14% VE against contracting the disease among fully vaccinated individuals. Factors such as age and underlying conditions significantly influenced VE. The findings of this study highlight the effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine in reducing the odds of symptomatic COVID-19, particularly by decreasing the prevalence of key symptoms such as fever, cough, myalgia, and loss of taste or smell. Breakthrough infections still occurred, indicating that while the vaccine reduces symptom severity, it may not fully prevent infection This VE is lower compared to previous variants, indicating potential challenges in vaccine efficacy. The study underscores the need for an on-going monitoring and potential booster doses to enhance protection, especially against evolving variants like Omicron.<\/jats:p>","DOI":"10.1371\/journal.pone.0318344","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T21:02:53Z","timestamp":1742504573000},"page":"e0318344","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-5441","authenticated-orcid":true,"given":"Maryo","family":"Baakliny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Maison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"9","key":"pone.0318344.ref001","doi-asserted-by":"crossref","first-page":"2000178","DOI":"10.2807\/1560-7917.ES.2020.25.9.2000178","article-title":"First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020","volume":"25","author":"G Spiteri","year":"2020","journal-title":"Euro Surveill"},{"key":"pone.0318344.ref002","author":"Centers for Disease Control and Prevention"},{"key":"pone.0318344.ref003","author":"World Health Organization","year":"2021 Mar 17"},{"issue":"13","key":"pone.0318344.ref004","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.3201\/eid2813.212248","article-title":"Leveraging international influenza surveillance systems and programs during the COVID-19 pandemic","volume":"28","author":"P Marcenac","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"pone.0318344.ref005","first-page":"1","article-title":"New coronavirus-infected pneumonia engulfs Wuhan","volume":"1","author":"QH Li","year":"2020","journal-title":"Asian Toxicology Research"},{"issue":"2","key":"pone.0318344.ref006","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.aej.2021.06.025","article-title":"The current COVID-19 pandemic in China: an overview and corona data analysis","volume":"61","author":"W Bo","year":"2022","journal-title":"Alexandria Engineering Journal"},{"key":"pone.0318344.ref007","author":"Worldometer"},{"key":"pone.0318344.ref008","author":"Ministry of Public Health Lebanon"},{"key":"pone.0318344.ref009","author":"Yale Medicine"},{"key":"pone.0318344.ref010","author":"European Centre for Disease Prevention and Control"},{"key":"pone.0318344.ref011"},{"issue":"2","key":"pone.0318344.ref012","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/vaccines11020224","article-title":"A systematic review and meta-analysis on the real-world effectiveness of COVID-19 Vaccines against infection, symptomatic and severe COVID-19 disease caused by the omicron variant (B.1.1.529)","volume":"11","author":"H Mohammed","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"pone.0318344.ref013","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJMoa2203209","article-title":"Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age","volume":"387","author":"SHX Tan","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0318344.ref014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in South Africa","volume":"386","author":"S Collie","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0318344.ref015","article-title":"Antibody tests for identification of current and past infection with SARS\u2010CoV\u20102","author":"T Fox","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T21:03:26Z","timestamp":1742504606000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318344"}},"subtitle":[],"editor":[{"given":"Marwan","family":"Osman,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0318344","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}